<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925129</url>
  </required_header>
  <id_info>
    <org_study_id>TENS MAB</org_study_id>
    <nct_id>NCT03925129</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Management With Medication Abortion Through 70 Days' Gestation</brief_title>
  <official_title>A Randomized, Placebo Controlled Trial of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Management With Medication Abortion Through 70 Days' Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood of New York City, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Planned Parenthood of New York City, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, randomized, placebo-controlled trial evaluating the use of
      High-frequency Transcutaneous Electrical Nerve Stimulation (HfTENS) compared to sham TENS for
      pain control during medication abortion with mifepristone and misoprostol through 70 days'
      gestation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain on numeric rating scale</measure>
    <time_frame>8 hours following misoprostol</time_frame>
    <description>Maximum pain score on an 11-point numeric rating scale, where 0 is no pain, and 10 is the worst pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Abortion in First Trimester</condition>
  <arm_group>
    <arm_group_label>TENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TENS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high frequency TENS treatment</intervention_name>
    <description>Treatment with high frequency for minimum of 1 hour after misoprostol administration</description>
    <arm_group_label>TENS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham TENS treatment</intervention_name>
    <description>Treatment with sham TENS device for minimum of 1 hour after misoprostol administration</description>
    <arm_group_label>Sham TENS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients seeking medication abortion with a definite, singleton, intrauterine
             pregnancy (IUP) &lt; 70 days' gestation on ultrasound

          -  Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF)22 score &gt; 4

          -  Age equal to or greater than 18 years

          -  Provide informed consent to participate

          -  Willing to adhere to study procedures, including access to a smart phone, ability to
             receive text messages and answer online surveys on smart phone

        Exclusion Criteria:

          -  Contraindication to medication abortion

          -  Allergy to mifepristone or misoprostol

          -  Contraindication or allergy to ibuprofen

          -  History of cardiac arrhythmia

          -  Presence of an implantable device with electrical discharge, i.e. cardiac pacemaker

          -  History of chronic pain disorder

          -  Any opioid use during previous 30 days

          -  Current or prior use of TENS

          -  BMI &gt; 30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Research Director</last_name>
    <phone>212-274-7340</phone>
    <email>ctri@ppnyc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Planned Parenthood of New York City - Margaret Sanger Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Director, MPH</last_name>
      <email>ctri@ppnyc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

